ITeos Therapeutics (ITOS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ITOS ITeos Therapeutics

Watchlist

7.420
+0.200+2.77%

Close Dec 20 16:00 ET

7.420
0.0000.00%

Post 16:13 ET

271.08MMarket Cap-2.36P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $19
Moomoo News13:43 ET · Ratings
ITeos Therapeutics Price Target Lowered to $19 From $31 at Wells Fargo
Yahoo FinanceDec 20 07:20 ET
Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $19
BenzingaDec 19 09:58 ET · Ratings
ITeos Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow JonesDec 13 06:37 ET · Ratings
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $21
Moomoo NewsDec 13 06:31 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $21 Price Target
BenzingaDec 13 06:27 ET

Comments

Jaguar8

Dec 12 07:55

NEWS

$ITeos Therapeutics (ITOS.US)$
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Thursday, 12th December at 8:55 am
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts
- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrat...

Gobinath

Sep 16 06:13

$ITeos Therapeutics (ITOS.US)$ 🤔

WarlockofWallstreet

May 13 11:34

ITOS

new strat paying off after days of running simulations, time to scaleup😅

lSlippyl

May 10 07:59

$ITeos Therapeutics (ITOS.US)$ Everyday some derpy stock with "therapeutics" in its name goes up 50%. we get it.

Moomoo AI

Mar 6 06:16

Jill DeSimone's appointment to iTeos' Board of Directors is a significant move. Her oncology expertise and business growth record are expected to contribute to iTeos' late-stage biopharmaceutical ambitions.